Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Feb;6(2):83-85.
doi: 10.1016/S2213-8587(17)30413-8. Epub 2017 Dec 6.

GLP-1 receptor agonists: differentiation within the class

Simeon I Taylor  1
Affiliations
Comment

GLP-1 receptor agonists: differentiation within the class

Simeon I Taylor. Lancet Diabetes Endocrinol. 2018 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure
Figure. Magnitude of cardioprotection is correlated with HbA1c-lowering
Hazard ratios from SUSTAIN-6, LEADER, EXSCEL, and ELIXA– are plotted on the vertical axis as a function of ‘normalized’ HbA1c-lowering plotted on the horizontal axis. To account for variation in study design among six head-to-head efficacy studies–, HbA1c-lowering data were normalized as follows:

  1. Normalized HbA1c-lowering for short-acting exenatide/BYETTA was defined as 1.00%.

  2. Normalized HbA1c-lowering for lixisenatide was calculated based on head-to-head comparative efficacy data obtained in the GetGoal-X study. Observed HbA1c-lowering was 0.96% for short-acting exenatide/BYETTA and 0.79% for lixisenatide, corresponding to an Efficacy Ratio of 0.82 (=0.79% / 0.96%). A normalized HbA1c-lowering for lixisenatide of 0.82% was calculated by multiplying the Efficacy Ratio (0.82) times the normalized HbA1c-lowering for short-acting exenatide (1.00%).

  3. Normalized HbA1c-lowering for long-acting exenatide/BYDUREON was calculated in a similar fashion based on comparative efficacy data in the DURATION-1 study. This yielded a value of 1.27% as the normalized HbA1c-lowering for long-acting exenatide [BYETTA].

  4. The DURATION-6 and SUSTAIN-3 studies reported Efficacy Ratios of 1.16 and 1.67 for liraglutide and semaglutide, respectively, relative to extended-release exenatide/BYDUREON. These calculations yield values for normalized HbA1c-lowering of 1.47% and 2.12% for liraglutide and semaglutide, respectively.

  5. The AWARD-6 and HARMONY-7 studies reported Efficacy Ratios of 1.04 and 0.79 for dulaglutide and albiglutide, respectively, relative to liraglutide. These calculations yield values for normalized HbA1c-lowering of 1.53% and 1.16% for dulaglutide and albiglutide, respectively.

See this image and copyright information in PMC

Comment in

Comment on

References

    1. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with GLP-1 receptor agonists: A meta-analysis. Lancet Diabetes Endocrinol. 2017 in press. - PubMed
    1. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311–22. - PMC - PubMed
    1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834–44. - PubMed
    1. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373:2247–57. - PubMed
    1. Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377:1228–39. - PMC - PubMed

Publication types